# National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Phase I Study on Safety and Efficacy of Mesenchymal Stem-Cell (MSC) Therapy in Non-Viral Acute-on-Chronic Liver Failure (ACLF)

> **NCT07131540** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Institute of Liver and Biliary Sciences, India** · enrollment: 10 (estimated)

## Conditions studied

- Acute-On-Chronic Liver Failure

## Interventions

- **DRUG:** umbilical cord Mesenchymal Stem Cell

## Key facts

- **NCT ID:** NCT07131540
- **Lead sponsor:** Institute of Liver and Biliary Sciences, India
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01
- **Primary completion:** 2031-12
- **Final completion:** 2031-12
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-08-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07131540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07131540, "National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Phase I Study on Safety and Efficacy of Mesenchymal Stem-Cell (MSC) Therapy in Non-Viral Acute-on-Chronic Liver Failure (ACLF)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07131540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*